請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/44382
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 蘇怡寧 | |
dc.contributor.author | Ti-I Chueh | en |
dc.contributor.author | 闕帝宜 | zh_TW |
dc.date.accessioned | 2021-06-15T02:54:21Z | - |
dc.date.available | 2010-09-15 | |
dc.date.copyright | 2009-09-15 | |
dc.date.issued | 2009 | |
dc.date.submitted | 2009-08-04 | |
dc.identifier.citation | 參考文獻
1.黃滄海, 運動與骨骼健康的原理與實務. 2005, 台灣台北: 合記圖書出版社. 3-9. 2.李明亮, 代謝性疾病 : 台灣經驗. 1 ed. 2004, 台灣台中: 合記圖書出版社. 287-296. 3.Marini, J.C., et al., Components of the collagen prolyl 3-hydroxylation complex are crucial for normal bone development. Cell Cycle, 2007. 6(14): p. 1675-81. 4.Cheung, M.S. and F.H. Glorieux, Osteogenesis Imperfecta: Update on presentation and management. Rev Endocr Metab Disord, 2008. 9(2): p. 153-60. 5.Morello, R., et al., CRTAP is required for prolyl 3- hydroxylation and mutations cause recessive osteogenesis imperfecta. Cell, 2006. 127(2): p. 291-304. 6.Cabral, W.A., et al., Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfecta. Nat Genet, 2007. 39(3): p. 359-65. 7.Gajko-Galicka, A., Mutations in type I collagen genes resulting in osteogenesis imperfecta in humans. Acta Biochim Pol, 2002. 49(2): p. 433-41. 8.陳淑華, 李玲慧, and 黃曉薇, 人類分子遺傳學. 1 ed. 2006, 台灣台北: 藝軒圖書出版社. 469-481. 9.Vranka, J.A., L.Y. Sakai, and H.P. Bachinger, Prolyl 3-hydroxylase 1, enzyme characterization and identification of a novel family of enzymes. J Biol Chem, 2004. 279(22): p. 23615-21. 10.Baldridge, D., et al., CRTAP and LEPRE1 mutations in recessive osteogenesis imperfecta. Hum Mutat, 2008. 11.Willaert, A., et al., Recessive Osteogenesis Imperfecta caused by LEPRE1 mutations: clinical documentation and identification of the splice form responsible for prolyl 3-hydroxylation. J Med Genet, 2008. 12.Glorieux, F.H., Osteogenesis imperfecta. Best Pract Res Clin Rheumatol, 2008. 22(1): p. 85-100. 13.Kataoka, K., et al., Mutations in type I collagen genes in Japanese osteogenesis imperfecta patients. Pediatr Int, 2007. 49(5): p. 564-9. 14.Sillence, D.O., Osteogenesis imperfecta nosology and genetics. Ann N Y Acad Sci, 1988. 543: p. 1-15. 15.Hackley, L. and L. Merritt, Osteogenesis imperfecta in the neonate. Adv Neonatal Care, 2008. 8(1): p. 21-30; quiz 31-2. 16.Rauch, F. and F.H. Glorieux, Osteogenesis imperfecta. Lancet, 2004. 363(9418): p. 1377-85. 17.Lin, H.Y., et al., Intravenous pamidronate therapy in Taiwanese patients with osteogenesis imperfecta. Pediatr Neonatol, 2008. 49(5): p. 161-5. 18.Horwitz, E.M., et al., Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood, 2001. 97(5): p. 1227-31. 19.Niyibizi, C., et al., Potential of gene therapy for treating osteogenesis imperfecta. Clin Orthop Relat Res, 2000(379 Suppl): p. S126-33. 20.Liew, M., et al., Genotyping of single-nucleotide polymorphisms by high-resolution melting of small amplicons. Clin Chem, 2004. 50(7): p. 1156-64. 21.Malmgren, B. and S. Lindskog, Assessment of dysplastic dentin in osteogenesis imperfecta and dentinogenesis imperfecta. Acta Odontol Scand, 2003. 61(2): p. 72-80. 22.Swinnen, F.K., et al., Audiometric, surgical, and genetic findings in 15 ears of patients with osteogenesis imperfecta. Laryngoscope, 2009. 119(6): p. 1171-9. 23.Kamoun-Goldrat, A., et al., A new osteogenesis imperfecta with improvement over time maps to 11q. Am J Med Genet A, 2008. 146A(14): p. 1807-14. 24.http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=oi. [cited. 25.Garnero, P., et al., Bone turnover and type I collagen C-telopeptide isomerization in adult osteogenesis imperfecta: associations with collagen gene mutations. Bone, 2009. 44(3): p. 461-6. 26.Redford-Badwal, D.A., et al., Nuclear retention of COL1A1 messenger RNA identifies null alleles causing mild osteogenesis imperfecta. J Clin Invest, 1996. 97(4): p. 1035-40. 27.Korkko, J., et al., Analysis of the COL1A1 and COL1A2 genes by PCR amplification and scanning by conformation-sensitive gel electrophoresis identifies only COL1A1 mutations in 15 patients with osteogenesis imperfecta type I: identification of common sequences of null-allele mutations. Am J Hum Genet, 1998. 62(1): p. 98-110. 28.Siegert, T., et al., [Osteogenesis imperfecta Type 1: a case presentation with a new mutation in gene COL1A1]. Klin Padiatr, 2004. 216(2): p. 91-3. 29.Forlino, A., et al., Severe (type III) osteogenesis imperfecta due to glycine substitutions in the central domain of the collagen triple helix. Hum Mol Genet, 1994. 3(12): p. 2201-6. 30.Lund, A.M., F. Skovby, and M. Schwartz, Serine for glycine substitutions in the C-terminal third of the alpha 1(I) chain of collagen I in five patients with nonlethal osteogenesis imperfecta. Hum Mutat, 1997. 9(4): p. 378-82. 31.Hartikka, H., et al., Lack of correlation between the type of COL1A1 or COL1A2 mutation and hearing loss in osteogenesis imperfecta patients. Hum Mutat, 2004. 24(2): p. 147-54 32.Pack, M., et al., Substitution of serine for alpha 1(I)-glycine 844 in a severe variant of osteogenesis imperfecta minimally destabilizes the triple helix of type I procollagen. The effects of glycine substitutions on thermal stability are either position of amino acid specific. J Biol Chem, 1989. 264(33): p. 19694-9. 33.Ries, L., et al., Prenatal diagnosis of a novel COL1A1 mutation in osteogenesis imperfecta type I carried through full term pregnancy. Prenat Diagn, 2000. 20(11): p. 876-80. 34.Zhuang, J., et al., Direct sequencing of PCR products derived from cDNAs for the pro alpha 1 and pro alpha 2 chains of type I procollagen as a screening method to detect mutations in patients with osteogenesis imperfecta. Hum Mutat, 1996. 7(2): p. 89-99. 35.Pollitt, R., et al., Mutation analysis of COL1A1 and COL1A2 in patients diagnosed with osteogenesis imperfecta type I-IV. Hum Mutat, 2006. 27(7): p. 716. 36.Marini, J.C., et al., Serine for glycine substitutions in type I collagen in two cases of type IV osteogenesis imperfecta (OI). Additional evidence for a regional model of OI pathophysiology. J Biol Chem, 1993. 268(4): p. 2667-73. 37.Marini, J.C., et al., Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans. Hum Mutat, 2007. 28(3): p. 209-21. 38.Willing, M.C., et al., Premature chain termination is a unifying mechanism for COL1A1 null alleles in osteogenesis imperfecta type I cell strains. Am J Hum Genet, 1996. 59(4): p. 799-809. 39.Wenstrup, R.J., et al., The effects of different cysteine for glycine substitutions within alpha 2(I) chains. Evidence of distinct structural domains within the type I collagen triple helix. J Biol Chem, 1991. 266(4): p. 2590-4. 40.Ward, L.M., et al., Thirty-three novel COL1A1 and COL1A2 mutations in patients with osteogenesis imperfecta types I-IV. Hum Mutat, 2001. 17(5): p. 434. 41.Xia, X.Y., et al., A novel RNA-splicing mutation in COL1A1 gene causing osteogenesis imperfecta type I in a Chinese family. Clin Chim Acta, 2008. 398(1-2): p. 148-51. 42.Byers, P.H., G.A. Wallis, and M.C. Willing, Osteogenesis imperfecta: translation of mutation to phenotype. J Med Genet, 1991. 28(7): p. 433-42. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/44382 | - |
dc.description.abstract | 摘 要
先天性成骨不全症(Osteogenesis imperfecta;O.I.),是一種因為骨骼結締組織異常所造成的遺傳疾病,其遺傳模式有自體顯性及自體隱性,發生率約為十萬分之6-7,目前臨床依照傳統的分型可以分成四型,在臨床診斷主要依照臨床表徵,然而我們的研究將進行相關基因檢測以及在基因型與表現型相關之探討。 我們進行了100個家族之先天性成骨不全症相關基因檢測,利用PCR、HRM、DHPLC以及基因定序等分生技術來完成,首先針對自體顯性的COL1A1、COL1A2基因來做檢測,在檢測未發現突變且並沒有家族史之家族,再繼續做自體隱性的CRTAP、LEPRE1和PPIB基因之檢測。 台灣在先天性成骨不全症之分佈O.I. type I為28%(26/92)、O.I. type II為12%(11/92)、O.I. type III為36%(33/92)、O.I. type IV為24%(22/92)。在這100個家族的基因檢測結果,46個家族有COL1A1基因的突變、25個家族有COL1A2基因的突變,在COL1A1、COL1A2基因的檢測率為71%,我們在從COL1A1、COL1A2基因檢測為陰性的家族,在PPIB基因之檢測發現到有1個家族有PPIB基因的突變(1/19)。 我們建立台灣在先天性成骨不全症之基因分析流程及資料庫,可以了解到台灣族群基因突變之點位以及易突變區域之分佈,進而快速完成基因檢測,提供在遺傳諮詢時明確的基因變異報告,以及在產前診斷相關之應用,在未來可做為先天性成骨不全症之基因及治療等研究之依據。 關鍵詞:先天性成骨不全症,基因檢測,COL1A1基因,COL1A2基因, CRTAP基因,LEPRE1基因,PPIB基因 | zh_TW |
dc.description.abstract | Abstract
Osteogenesis imperfecta (OI) is a heritable disorder of bone formation﹐which is characterized by bone fragility and low bone mass﹒As reported, Autosomal dominant OI is associated with the mutations of COL1A1 and COL1A2 genes. Autosomal recessive OI is association of CRTAP、LEPRE1 and PPIB gene﹒ In this study, exon-wide mutation analysis of COL1A1、COL1A2、CRTAP、LEPRE1and PPIB genes in osteogenesis imperfecta originated from Taiwan population by molecular diagnosis coupling several mutation detection techniques including Denaturing High Performance Liquid Chromatography (DHPLC), High-Resolution Melting analysis (HRM), and automated sequencing analysis was performed. One hundred unrelated patients and their family members diagnosed with OI clinically were enrolled in this study. Forty-six patients had mutation in COL1A1 gene﹐25 in COL1A2 gene. The mutation detection rate of COL1A1 and COL1A2 genes is 71%﹒Furthermore, 19 patients without mutation identified in COL1A1/ COL1A2 gene were analyzed for the possible mutations in CRTAP、LEPRE1and PPIB genes﹒One patient had mutation in PPIB gene was identified (1/19). No mutation in CRTAP or LEPRE1 gene was found. To gain more insight into the mutational spectrum in Taiwanese patients with OI﹐ we conducted this study to perform extensive exon-wide mutational analysis of COL1A1、COL1A2、CRTAP、LEPRE1and PPIB genes based on the high- throughput mutation scanning system with DHPLC and HRM system﹒There are several hot mutation regions in COL1A1 and COL1A2 gene had been proposed﹒However, further studies to elucidate the genotype-phenotype correlation are still warrant. Key word:Osteogenesis imperfecta﹐mutation analysis﹐COL1A1 gene﹐COL1A2 gene﹐CRTAP gene,LEPRE1 gene﹐PPIB gene﹐High-Resolution Melting analysis (HRM)﹐Denaturing High Performance Liquid Chromatography (DHPLC) | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T02:54:21Z (GMT). No. of bitstreams: 1 ntu-98-P96448002-1.pdf: 1248957 bytes, checksum: 540a64d9f1665d70e1d0071d3e51cd98 (MD5) Previous issue date: 2009 | en |
dc.description.tableofcontents | 目 錄
圖目錄..................................................i 表目錄..................................................ii 中文摘要................................................iii 英文摘要................................................iv 第一章 緒論...........................................1 1.1 骨骼之結構....................................1 1.2 膠原蛋白之結構................................2 1.3 COL1A1和COL1A2基因之介紹......................3 1.4 膠原蛋白之顯性負向效應........................3 1.5 LEPRE1、CRTAP、PPIB基因之介紹.................4 1.6 臨床表現與診斷................................5 1.7 疾病分型......................................5 1.8 先天性成骨不全症之發生率......................6 1.9 治療..........................................6 1.10 遺傳諮詢......................................6 1.11 研究動機......................................7 第二章 實驗材料與儀器.................................8 2.1 實驗材料.......................................8 2.1.1 先天性成骨不全症基因檢測之DNA檢體.................8 2.1.2 引子對............................................8 2.1.3 聚合酶連鎖反應試劑................................8 2.1.4 洋菜膠電泳試劑....................................8 2.1.5 DHPLC試劑組......................................9 2.1.6 HRM試劑組........................................9 2.1.7 DNA定序試劑......................................9 2.2 實驗儀器.......................................9 2.2.1 磁珠分離式核酸萃取系統...........................9 2.2.2 PCR熱循環機......................................9 2.2.3 DHPLC分析儀......................................9 2.2.4 HRM分析儀........................................9 2.2.5 DNA序列分析儀....................................9 第三章 實驗方法......................................10 3.1 DNA抽取.......................................10 3.2 聚合酶連鎖反應(PCR).........................10 3.3 洋菜膠電泳(Agarose gel electrophoresis)......10 3.4 DNA突變分析(DHPLC)..........................10 3.5 高解析基因突變篩檢分析(HRM).................11 3.6 正常族群單一核苷酸多型性分析..................11 3.7 自動定序分析(Automated sequencing)..........11 第四章 實驗結果......................................12 4.1 先天性成骨不全症之疾病表現型與臨床表徵之統計..12 4.2 先天性成骨不全症之基因檢測結果................12 4.3 先天性成骨不全症疾病的表現型與基因型之相關....13 4.4 COL1A1、COL1A2基因與突變形態之分佈統計........14 4.5 第一型前膠原蛋白α1和α2功能區上表現型與突變 形態之分佈統計................................15 4.6 COL1A1、COL1A2基因高發生突變區域..............15 4.7 先天性成骨不全症相關基因之單一核苷酸多型性....16 第五章 討論..........................................17 第六章 結論..........................................23 第七章 參考文獻......................................24 | |
dc.language.iso | zh-TW | |
dc.title | 台灣先天性成骨不全症之基因檢測 | zh_TW |
dc.title | Genetic Analysis of Osteogenesis Imperfecta in Taiwan | en |
dc.type | Thesis | |
dc.date.schoolyear | 97-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 楊偉勛,林炫沛 | |
dc.subject.keyword | 先天性成骨不全症,基因檢測,COL1A1基因,COL1A2基因,CRTAP基因,LEPRE1基因,PPIB基因, | zh_TW |
dc.subject.keyword | Osteogenesis imperfecta,mutation analysis,COL1A1 gene,COL1A2 gene,CRTAP gene,LEPRE1 gene,PPIB gene,High-Resoution Melting analysis(HRM),Denaturing High Performance Liquid Chromatography (DHPLC), | en |
dc.relation.page | 69 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2009-08-04 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 分子醫學研究所 | zh_TW |
顯示於系所單位: | 分子醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-98-1.pdf 目前未授權公開取用 | 1.22 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。